drug
DARZALEX FASPRO
updated 3mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
Trials studying DARZALEX FASPRO
- phase1A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- phase2ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
- phase4Home Based Daratumumab Administration for Patients With Multiple Myeloma
- phase2Teclistamab-Daratumumab in AL Amyloidosis
- phase2Daratumumab in HLA Desensitization Prior to Transplantation
- phase2Daratumumab for Polyneuropathy Associated With MGUS
- EP1Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- phase3A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
News(1)
- J&J multiple myeloma drug gains edge in earlier stage diseaseThe latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.biopharma_dive · 2mo ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that